Welcome to our dedicated page for Palatin Tech SEC filings (Ticker: PTN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech disclosure shouldn’t feel like decoding a lab notebook, yet Palatin Technologies’ SEC documents are packed with clinical data tables, cash-runway projections and detailed licensing terms. If you’re searching for Palatin Technologies SEC filings explained simply, or wondering how the latest 8-K material event affects trial timelines, you’re in the right place.
Stock Titan’s AI quickly dissects every filing type—whether it’s a Palatin Technologies quarterly earnings report 10-Q filing outlining R&D spend, an 8-K announcing Phase 2 results, or a shelf registration that could dilute shareholders. Our algorithm highlights the sections that matter: safety signals, FDA correspondence, partnership revenue and dilution triggers. You can also track Palatin Technologies Form 4 insider transactions real-time, receive instant summaries of executive stock moves and view a plain-language breakdown of the Palatin Technologies annual report 10-K simplified.
Use this page to:
- Monitor Palatin Technologies executive stock transactions Form 4 before key clinical readouts
- Compare quarter-over-quarter trial expenses with our Palatin Technologies earnings report filing analysis
- Dive into the definitive proxy for Palatin Technologies proxy statement executive compensation details
- See every Palatin Technologies insider trading Form 4 transactions alert the moment it hits EDGAR
- Get concise explanations of Palatin Technologies 8-K material events explained by AI
Whether you’re assessing cash burn, partnership economics or potential dilution, our platform turns hundreds of pages into actionable insights—helping you understand understanding Palatin Technologies SEC documents with AI in minutes, not hours.
Palatin Technologies, Inc. will implement a 1-for-50 reverse stock split approved by shareholders and the board, expected to become effective after market on August 11, 2025, with shares trading on a split-adjusted basis on the OTCQB at market open on August 12, 2025. The company was previously determined not suitable for NYSE American listing due to a low selling price; trading was suspended May 7, 2025, and the stock has since traded on OTC Pink and then OTCQB under the symbol PTNT. The timing change reflects a delayed FINRA approval now expected after market on August 11, 2025.
Palatin Technologies completed a 1-for-50 reverse stock split approved by shareholders, effective August 8, 2025 at 5:00 p.m. ET. The action combines every 50 shares into one share while leaving the par value and other terms unchanged. Shares are expected to trade on the OTCQB on a split-adjusted basis beginning August 11, 2025 and will use the temporary ticker PTNTD for 20 trading days.
The company disclosed that NYSE American determined the common stock was no longer suitable for listing due to a low selling price and commenced delisting proceedings, with trading suspended on May 7, 2025. The stock traded on the Pink Market May 8–June 6, 2025 and has traded on the OTCQB since June 9, 2025. Fractional shares will be paid in cash based on the five-day average closing price prior to August 8, 2025.
FAQ
What is the current stock price of Palatin Tech (PTN)?
What is the market cap of Palatin Tech (PTN)?
